Brokerages predict that Enanta Pharmaceuticals Inc (NASDAQ:ENTA) will post earnings per share (EPS) of $1.57 for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Enanta Pharmaceuticals’ earnings. The lowest EPS estimate is $1.35 and the highest is $1.73. Enanta Pharmaceuticals reported earnings per share of $0.78 during the same quarter last year, which would suggest a positive year over year growth rate of 101.3%. The company is expected to report its next quarterly earnings report after the market closes on Wednesday, February 6th.
According to Zacks, analysts expect that Enanta Pharmaceuticals will report full-year earnings of $1.58 per share for the current financial year, with EPS estimates ranging from $0.30 to $2.38. For the next year, analysts anticipate that the firm will report earnings of ($1.47) per share, with EPS estimates ranging from ($2.72) to ($0.12). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Enanta Pharmaceuticals.
Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Monday, November 26th. The biotechnology company reported $1.30 EPS for the quarter, topping the Zacks’ consensus estimate of $1.24 by $0.06. Enanta Pharmaceuticals had a return on equity of 21.56% and a net margin of 34.82%. The business had revenue of $67.20 million during the quarter, compared to analyst estimates of $69.03 million. During the same quarter last year, the company earned $1.86 EPS. The company’s quarterly revenue was down 11.5% compared to the same quarter last year.
Several research analysts have weighed in on ENTA shares. Zacks Investment Research upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, December 3rd. Oppenheimer set a $100.00 price target on shares of Enanta Pharmaceuticals and gave the stock a “hold” rating in a research report on Tuesday, November 27th. TheStreet downgraded Enanta Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Monday, November 26th. BidaskClub raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, November 2nd. Finally, ValuEngine cut Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 8th. Six equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $100.00.
Institutional investors have recently added to or reduced their stakes in the business. Navellier & Associates Inc increased its holdings in shares of Enanta Pharmaceuticals by 12.1% in the 4th quarter. Navellier & Associates Inc now owns 29,594 shares of the biotechnology company’s stock worth $2,096,000 after purchasing an additional 3,201 shares in the last quarter. Thrivent Financial for Lutherans increased its position in shares of Enanta Pharmaceuticals by 9.4% during the 3rd quarter. Thrivent Financial for Lutherans now owns 10,849 shares of the biotechnology company’s stock worth $927,000 after purchasing an additional 936 shares in the last quarter. HL Financial Services LLC bought a new stake in shares of Enanta Pharmaceuticals in the third quarter valued at about $3,870,000. BlackRock Inc. lifted its holdings in shares of Enanta Pharmaceuticals by 6.5% in the 3rd quarter. BlackRock Inc. now owns 2,590,166 shares of the biotechnology company’s stock worth $221,354,000 after purchasing an additional 157,166 shares in the last quarter. Finally, Victory Capital Management Inc. purchased a new position in Enanta Pharmaceuticals in the 3rd quarter worth approximately $245,000. Hedge funds and other institutional investors own 84.95% of the company’s stock.
NASDAQ:ENTA opened at $76.92 on Friday. The stock has a market cap of $1.49 billion, a PE ratio of 22.10 and a beta of 0.99. Enanta Pharmaceuticals has a 52 week low of $64.08 and a 52 week high of $127.77.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.
See Also: Understanding Relative Strength Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.